A Prospective Multicenter Randomized Controlled Study on Interleukin-6 Removal and Induction by a new Hemodialyzer With Improved Biocompatibility in Hemodialysis Patients: A Pilot Study
- PMID: 27501003
- DOI: 10.1111/1744-9987.12454
A Prospective Multicenter Randomized Controlled Study on Interleukin-6 Removal and Induction by a new Hemodialyzer With Improved Biocompatibility in Hemodialysis Patients: A Pilot Study
Abstract
We compared interleukin-6 (IL-6) removal and induction between conventional polysulfone (Con) and TORAYLIGHT NV (NV) dialyzers in hemodialysis patients. Twenty patients on Con with high IL-6 concentrations (2.7-8.5 pg/mL) were randomized to Con or NV group. Dialyzer performance was determined in NV group while patients were on Con and after being switched onto NV. Erythropoiesis-stimulating agent (ESA) response index (ERI) was assessed every 4 months for one year. IL-6 clearance was comparable between Con and NV. IL-6 removal rates were comparable for the first 1 h, but were higher with NV for the entire session (P = 0.03). Before-to-during-dialysis IL-6 concentration ratios were lower with NV on the venous side after the session (P = 0.03). During the one-year study, hemoglobin was lower in Con group than in NV group at month 8 (P = 0.046). ERI decreased in NV and increased in Con group, with a significant difference between the groups (P = 0.002). NV and Con are comparable in removing IL-6 and both induce IL-6. However, the data suggest that NV induces less IL-6, which may reduce the risk of ESA hyporesponsiveness.
Keywords: Biocompatibility; Erythropoiesis stimulating agent; Hemodialysis; Inflammatory cytokine.
© 2016 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Similar articles
-
A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti-Platelet Activation Membrane Dialyzer in Hemodialysis Patients.Ther Apher Dial. 2019 Apr;23(2):133-144. doi: 10.1111/1744-9987.12759. Epub 2018 Oct 11. Ther Apher Dial. 2019. PMID: 30311350 Free PMC article.
-
A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial.Blood Purif. 2011;32(1):7-14. doi: 10.1159/000321369. Epub 2011 Jan 14. Blood Purif. 2011. PMID: 21242686 Clinical Trial.
-
Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.BMC Nephrol. 2015 Jun 5;16:79. doi: 10.1186/s12882-015-0074-9. BMC Nephrol. 2015. PMID: 26045064 Free PMC article.
-
Randomized controlled open-label trial of vitamin E-bonded polysulfone dialyzer and erythropoiesis-stimulating agent response.Clin J Am Soc Nephrol. 2013 Jun;8(6):969-78. doi: 10.2215/CJN.04680512. Epub 2013 Apr 18. Clin J Am Soc Nephrol. 2013. PMID: 23599410 Free PMC article. Clinical Trial.
-
Haemodialyser reuse: facts and fiction.Nephrol Dial Transplant. 2000 Jan;15(1):5-8. doi: 10.1093/ndt/15.1.5. Nephrol Dial Transplant. 2000. PMID: 10607759 Review. No abstract available.
Cited by
-
Effects of Diet and Supplements on Parameters of Oxidative Stress, Inflammation, and Antioxidant Mechanisms in Patients with Chronic Renal Failure Undergoing Hemodialysis.Int J Mol Sci. 2024 Oct 14;25(20):11036. doi: 10.3390/ijms252011036. Int J Mol Sci. 2024. PMID: 39456817 Free PMC article.
-
What is the role of the neutrophil extracellular traps in the cardiovascular disease burden associated with hemodialysis bioincompatibility?Front Med (Lausanne). 2023 Nov 15;10:1268748. doi: 10.3389/fmed.2023.1268748. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38034546 Free PMC article. Review.
-
Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son".Toxins (Basel). 2017 Mar 23;9(4):114. doi: 10.3390/toxins9040114. Toxins (Basel). 2017. PMID: 28333114 Free PMC article. Review.
-
Biocompatibility of Surface-Modified Membranes for Chronic Hemodialysis Therapy.Biomedicines. 2022 Apr 3;10(4):844. doi: 10.3390/biomedicines10040844. Biomedicines. 2022. PMID: 35453594 Free PMC article. Review.
-
Interleukin-6 Contributes to the Development of Anemia in Juvenile CKD.Kidney Int Rep. 2018 Dec 19;4(3):470-483. doi: 10.1016/j.ekir.2018.12.006. eCollection 2019 Mar. Kidney Int Rep. 2018. PMID: 30899874 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical